Comparison of the Tamsulosin and Tolterodine Effectiveness in Stent-Related Symptoms Reduction

Introduction To compare the effectiveness of tamsulosin and Tolterodine in reducing stent-related symptoms with each other and with the control group we performed this randomized clinical trial. Methods 150 patients after successful first-time transurethral lithotripsy (TUL) for unilateral ureter...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Seyed Amin Mirsadeghi, Seyed Saeed Tamehri Zadeh, Alimohammad Fakhr Yasseri, Ali Tabibi, Mohammad Hadi Radfar, Diana Taheri
Formato:	article
Lenguaje:	EN
Publicado:	Urology Research Center 2021
Materias:	ureteral stent tamsulosin tolterodine Diseases of the genitourinary system. Urology RC870-923
Acceso en línea:	https://doaj.org/article/3a338319379b43b99cf8133b360d46ac
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3a338319379b43b99cf8133b360d46ac
record_format	dspace
spelling	oai:doaj.org-article:3a338319379b43b99cf8133b360d46ac2021-11-27T06:34:19ZComparison of the Tamsulosin and Tolterodine Effectiveness in Stent-Related Symptoms Reduction10.22034/TRU.2021.256708.10422717-042Xhttps://doaj.org/article/3a338319379b43b99cf8133b360d46ac2021-02-01T00:00:00Zhttps://www.transresurology.com/article_125425.htmlhttps://doaj.org/toc/2717-042XIntroduction To compare the effectiveness of tamsulosin and Tolterodine in reducing stent-related symptoms with each other and with the control group we performed this randomized clinical trial. Methods 150 patients after successful first-time transurethral lithotripsy (TUL) for unilateral ureteral stones were elected for the study 17 patients were excluded in the first allocation. Other patients were randomized (With balanced blocked randomization) into three groups. In group 1, 41 patients received Tamsulosin (Omnic) 0.4mg once a day for a month and in group 2, 42 patients received tolterodine (Detrusitol) 2mg once a day for a month. In group 3, which was our control group, 50 patients received a placebo once a day for a month. Clinical stent-related symptoms questionnaires at the first visit (day 10) and before removing themes stent were completed. Two urine tests and an x-ray of the abdomen in the first visit have been performed. Results Despite the remarkable decrease in the severity of stent-related symptoms other than urine urgency in the control group (p-value<0.05), solitary use of neither tamsulosin nor tolterodine was superior to the control group, and also, they were not superior to each other with respect to improving double-J stent-related symptoms (p-value>0.05). Conclusion The results of our study show that administration of tolterodine and tamsulosin to reduce stent-related symptoms do not have superiority to each other and the control group.Seyed Amin MirsadeghiSeyed Saeed Tamehri ZadehAlimohammad Fakhr Yasseri Ali Tabibi Mohammad Hadi Radfar Diana TaheriUrology Research Centerarticleureteral stenttamsulosintolterodineDiseases of the genitourinary system. UrologyRC870-923ENTranslational Research in Urology, Vol 3, Iss 1, Pp 23-31 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ureteral stent tamsulosin tolterodine Diseases of the genitourinary system. Urology RC870-923
spellingShingle	ureteral stent tamsulosin tolterodine Diseases of the genitourinary system. Urology RC870-923 Seyed Amin Mirsadeghi Seyed Saeed Tamehri Zadeh Alimohammad Fakhr Yasseri Ali Tabibi Mohammad Hadi Radfar Diana Taheri Comparison of the Tamsulosin and Tolterodine Effectiveness in Stent-Related Symptoms Reduction
description	Introduction To compare the effectiveness of tamsulosin and Tolterodine in reducing stent-related symptoms with each other and with the control group we performed this randomized clinical trial. Methods 150 patients after successful first-time transurethral lithotripsy (TUL) for unilateral ureteral stones were elected for the study 17 patients were excluded in the first allocation. Other patients were randomized (With balanced blocked randomization) into three groups. In group 1, 41 patients received Tamsulosin (Omnic) 0.4mg once a day for a month and in group 2, 42 patients received tolterodine (Detrusitol) 2mg once a day for a month. In group 3, which was our control group, 50 patients received a placebo once a day for a month. Clinical stent-related symptoms questionnaires at the first visit (day 10) and before removing themes stent were completed. Two urine tests and an x-ray of the abdomen in the first visit have been performed. Results Despite the remarkable decrease in the severity of stent-related symptoms other than urine urgency in the control group (p-value<0.05), solitary use of neither tamsulosin nor tolterodine was superior to the control group, and also, they were not superior to each other with respect to improving double-J stent-related symptoms (p-value>0.05). Conclusion The results of our study show that administration of tolterodine and tamsulosin to reduce stent-related symptoms do not have superiority to each other and the control group.
format	article
author	Seyed Amin Mirsadeghi Seyed Saeed Tamehri Zadeh Alimohammad Fakhr Yasseri Ali Tabibi Mohammad Hadi Radfar Diana Taheri
author_facet	Seyed Amin Mirsadeghi Seyed Saeed Tamehri Zadeh Alimohammad Fakhr Yasseri Ali Tabibi Mohammad Hadi Radfar Diana Taheri
author_sort	Seyed Amin Mirsadeghi
title	Comparison of the Tamsulosin and Tolterodine Effectiveness in Stent-Related Symptoms Reduction
title_short	Comparison of the Tamsulosin and Tolterodine Effectiveness in Stent-Related Symptoms Reduction
title_full	Comparison of the Tamsulosin and Tolterodine Effectiveness in Stent-Related Symptoms Reduction
title_fullStr	Comparison of the Tamsulosin and Tolterodine Effectiveness in Stent-Related Symptoms Reduction
title_full_unstemmed	Comparison of the Tamsulosin and Tolterodine Effectiveness in Stent-Related Symptoms Reduction
title_sort	comparison of the tamsulosin and tolterodine effectiveness in stent-related symptoms reduction
publisher	Urology Research Center
publishDate	2021
url	https://doaj.org/article/3a338319379b43b99cf8133b360d46ac
work_keys_str_mv	AT seyedaminmirsadeghi comparisonofthetamsulosinandtolterodineeffectivenessinstentrelatedsymptomsreduction AT seyedsaeedtamehrizadeh comparisonofthetamsulosinandtolterodineeffectivenessinstentrelatedsymptomsreduction AT alimohammadfakhryasseri comparisonofthetamsulosinandtolterodineeffectivenessinstentrelatedsymptomsreduction AT alitabibi comparisonofthetamsulosinandtolterodineeffectivenessinstentrelatedsymptomsreduction AT mohammadhadiradfar comparisonofthetamsulosinandtolterodineeffectivenessinstentrelatedsymptomsreduction AT dianataheri comparisonofthetamsulosinandtolterodineeffectivenessinstentrelatedsymptomsreduction
_version_	1718409157746360320

Comparison of the Tamsulosin and Tolterodine Effectiveness in Stent-Related Symptoms Reduction

Ejemplares similares